The aim of this study was to examine the association between genetically proxied inhibition of lipid-lowering drug targets (i.e., PCSK9, NPC1L1, HMGCR) and prostate cancer using evidence from multiple datasets and analytical methods. Here, HMGCR is linked to Familial prostate cancer.